Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: A meta-analysis and systematic review

International Journal of Ophthalmology

Volumn 9, Issue 7, 2016, Pages 1028-1037

  Tong, Yao ^a,b   Zhao, Ke Ke ^b   Feng, Dong ^c   Biswal, Manas ^d   Zhao, Pei Quan ^b   Wang, Zhao Yang ^b   Zhang, Yun ^a  

^a EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Age related macular degeneration; Anti vascular endothelial growth factor; Meta analysis; Photodynamic therapy

Indexed keywords

EID: 84983474760     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.18240/ijo.2016.07.16     Document Type: Article

References (20)

1. VanNewkirk MR, Weih LM, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the visual impairment project. Ophthalmology. 2001;108(5):960–967.
2. Harvey PT. Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology. 2003;49(1):1–11.
3. Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564–572.
4. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, Mitchell P, Wong TY. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology.2010;117(5):921–927.
5. Kaiser PK. Verteporfin photodynamic therapy and antiangiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin. 2007;23(3):477–487.
6. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157(1):135–144.
7. Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina (Philadelphia, Pa) 2009;29(6 Suppl):S5–S7.
8. Verteporfin in Photodynamic Therapy Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541–560.
9. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol.2001;119(2):198–207.
10. Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no 8. Graefes Arch Clin Exp Ophthalmol. 2006;244(9):1132–1142.
11. Wolf-Schnurrbusch UE, Brinkmann CK, Berger L, Wolf S. Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration. Acta Ophthalmol. 2011;89(6):585–590.
12. Williams PD, Callanan D, Solley W, Avery RL, Pieramici DJ, Aaberg T. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol.2012;6:1519–1525.
13. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC. A randomised prospective doublemasked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24(10):1561–1567.
14. Lim JY, Lee SY, Kim JG, Lee JY, Chung H, Yoon YH. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol. 2012;90(1):61–67.
15. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, Pilz S, Weisberger A, MONT BLANC Study Group Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992–1000.
16. Krebs I, Vécsei Marlovits V, Bodenstorfer J, Glittenberg C, Ansari Shahrezaei S, Ristl R, Binder S. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmol. 2013;91(3):e178–e183.
17. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A, DENALI Study Group Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001–1010.
18. Datseris I, Kontadakis GA, Diamanti R, Datseris I, Pallikaris IG, Theodossiadis P, Tsilimbaris MK. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration. Semin Ophthalmol. 2015;30(2):112–117.
19. Costagliola C, Romano MR, Rinaldi M, dell’Omo R, Chiosi F, Menzione M, Semeraro F. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Br J Ophthalmol. 2010;94(2):180–184.
20. Si JK, Tang K, Bi HS, Guo DD, Guo JG, Du YX, Cui Y, Pan XM, Wen Y, Wang XR. Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials. Int J Ophthalmol.2014;7(3):541–549.